Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study

Tofacitinib (TOFA), a member of a new class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), is a promising medication for the treatment of rheumatoid arthritis (RA) and other immunoinflammatory diseases. The paper describes the Russian experi-ence with TOFA used to treat severe...

Full description

Bibliographic Details
Main Authors: D. E. Karateev, D. E. Abdulganieva, A. R. Babaeva, A. A. Baranov, L. P. Evstigneeva, O. N. Ivanova, G. V. Lukina, E. L. Luchikhina, V. I. Mazurov, A. S. Misiyuk, O. V. Semagina, A. E. Sizikov, V. N. Sorotskaya
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2016-09-01
Series:Современная ревматология
Subjects:
ревматоидный артрит
резистентность к терапии
базисные противовоспалительные препараты
тофацитиниб
Online Access:https://mrj.ima-press.net/mrj/article/view/702

Internet

https://mrj.ima-press.net/mrj/article/view/702

Similar Items